Gene: ATP2C2

9914
SPCA2
ATPase secretory pathway Ca2+ transporting 2
protein-coding
16q24.1
Ensembl:ENSG00000064270 MIM:613082 Vega:OTTHUMG00000176737 UniprotKB:O75185
NC_000016.10
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  4.246e-1 (ND)   (Frontal_Cortex)
1.295e-1 (AD)  8.806e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs17815700chr16:84455427 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs16973814chr16:84446014 (GRCh38.p7)G>A / G>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg04342425chr16:84475861ATP2C2Gene body1.493e-4Alcohol use disorders26763658
cg07277633chr16:84402496ATP2C2Gene body6.329e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASIC10.715
FLRT10.671
CHRNA40.665
LRRN20.66
ASTN20.657
KCNIP30.64
TRIM670.64
GRIK40.639
KIF21B0.637
ETV10.635

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MS4A6A-0.513
CLEC2B-0.511
CD163-0.504
RNASE2-0.502
GBP2-0.499
MS4A4A-0.494
NCF4-0.492
CFI-0.491
SLC11A1-0.49
VSIG4-0.488

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
D017639Asbestos, Amosite"Asbestos, Amosite results in increased expression of ATP2C2 mRNA"23917077
D001280AtrazineAtrazine results in decreased expression of ATP2C2 mRNA26476475
D001280Atrazinelycopene inhibits the reaction [Atrazine results in decreased expression of ATP2C2 mRNA]26476475
C547126AZM551248AZM551248 results in decreased expression of ATP2C2 mRNA22323515
C547126AZM551248AZM551248 results in increased expression of ATP2C2 mRNA22323515
C006780bisphenol Abisphenol A results in decreased expression of ATP2C2 mRNA26063408
C006780bisphenol Abisphenol A results in decreased expression of ATP2C2 mRNA25181051
D002104CadmiumCadmium results in decreased expression of ATP2C2 mRNA21167921
C018021cobaltous chloridecobaltous chloride results in decreased expression of ATP2C2 mRNA24386269
C118739entinostatentinostat results in increased expression of ATP2C2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
D005419FlavonoidsFlavonoids results in increased expression of ATP2C2 mRNA18035473
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of ATP2C2 mRNA"24972896
C015329lycopenelycopene inhibits the reaction [Atrazine results in decreased expression of ATP2C2 mRNA]26476475
D008727MethotrexateMethotrexate results in decreased expression of ATP2C2 mRNA24449571
C523799MRK 003ATP2C2 results in decreased susceptibility to MRK 00319903844
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of ATP2C2 mRNA26272509
D011374ProgesteroneNCOA2 protein affects the reaction [Progesterone results in increased expression of ATP2C2 mRNA]17556502
D011374ProgesteroneProgesterone results in increased expression of ATP2C2 mRNA17556502
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ATP2C2 mRNA25895662
C009495titanium dioxidetitanium dioxide results in decreased expression of ATP2C2 mRNA23557971
D014212TretinoinTretinoin results in increased expression of ATP2C2 mRNA20488242
C012589trichostatin Atrichostatin A results in increased expression of ATP2C2 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of ATP2C2 mRNA23179753|2438349

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005388calcium-transporting ATPase activity-IBA21873635  
GO:0005388calcium-transporting ATPase activity-IEA-  
GO:0005515protein binding-IPI20887894  
GO:0005524ATP binding-IEA-  
GO:0008553proton-exporting ATPase activity, phosphorylative mechanism-IBA21873635  
GO:0015410manganese-transporting ATPase activity-IBA21873635  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006874cellular calcium ion homeostasis-IBA21873635  
GO:0070588calcium ion transmembrane transport-IBA21873635  
GO:0070588calcium ion transmembrane transport-IEA-  
GO:0099132ATP hydrolysis coupled cation transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IBA21873635  
GO:0000139Golgi membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-382551Transport of small moleculesTAS
R-HSA-936837Ion transport by P-type ATPasesTAS
R-HSA-983712Ion channel transportTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal